MAP2K7 and melanoma: 50% of patients develop resistance to BRAF and MEK inhibitors within 6–7 months of initiating treatment (Flaherty et al., 2012; Wood and Luke, 2016), underscoring the persistence of melanoma as a significant clinical challenge.